Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib, Sintilimab, and Temozolomide in R/R CNS Lymphoma
NCT04961515Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jul 2021
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of orelabrutinib in central nervous system lymphoma, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Objective Response Rate at 2 years. Started Jul 2021; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
central nervous system lymphoma
Beyond the preview
Go deeper on NCT04961515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04961515.